Haleon plc Discloses Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Aug 28, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, disclosure
TL;DR
Haleon bought back its own shares on 8/28/25. Details light.
AI Summary
Haleon plc announced on August 28, 2025, that it conducted a transaction in its own shares. The filing, a Form 6-K, details this activity without specifying the exact number of shares or the total value involved in the transaction.
Why It Matters
This filing indicates corporate actions related to Haleon's own stock, which can influence share price and investor perception.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share transactions and does not contain negative financial news or significant operational changes.
Key Players & Entities
- Haleon plc (company) — Registrant
- August 28, 2025 (date) — Date of transaction in own shares
- 001-41411 (other) — Commission File Number
FAQ
What type of transaction did Haleon plc conduct in its own shares on August 28, 2025?
Haleon plc conducted a transaction in its own shares on August 28, 2025, as detailed in Exhibit 99.1 of the Form 6-K filing.
What is the filing type and date for this disclosure?
The filing type is a Form 6-K, and it is dated for the month of August 2025, with the specific transaction date being August 28, 2025.
What is Haleon plc's principal executive office address?
Haleon plc's principal executive offices are located at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Does Haleon plc file its annual reports under Form 20-F or Form 40-F?
Haleon plc indicates that it files its annual reports under cover of Form 20-F.
What was Haleon plc's former name?
Haleon plc's former name was DRVW 2022 Ltd, with a date of name change on December 17, 2021.
Filing Stats: 564 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-08-28 06:29:08
Filing Documents
- a9461w.htm (6-K) — 31KB
- a9461w000.jpg (GRAPHIC) — 3KB
- 0001654954-25-010112.txt ( ) — 37KB
From the Filing
IN OWN SHARES a9461w   UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of August 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 28 August 2025 - Transaction in Own Shares     99.1           Haleon plc:   Transaction in own shares     28 August 2025:  Haleon plc (the "Company" or "Haleon") today announces the purchase of 2,875,831 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 27 August 2025 27 August 2025 27 August 2025 Number of Shares purchased: 2,875,831 - - Highest price paid per Share (p): 363.7000 - - Lowest price paid per Share (p): 359.2000 - - Volume weighted average price paid per Share (p): 361.3796 - -   Following the settlement of the above, the Company's registered share capital is 8,963,475,311 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,959,595,106 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.     In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/9460W_1-2025-8-27.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:  www.haleon.com/investors .     Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zoë Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:  investor-relations@haleon.com Email:  corporate.media@haleon.com     About Haleon   Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit  www.haleon.com .      SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: August 28, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary